PL3463351T3 - Leczenie choroby parkinsona - Google Patents

Leczenie choroby parkinsona

Info

Publication number
PL3463351T3
PL3463351T3 PL17743097T PL17743097T PL3463351T3 PL 3463351 T3 PL3463351 T3 PL 3463351T3 PL 17743097 T PL17743097 T PL 17743097T PL 17743097 T PL17743097 T PL 17743097T PL 3463351 T3 PL3463351 T3 PL 3463351T3
Authority
PL
Poland
Prior art keywords
parkinson
disease
treatment
Prior art date
Application number
PL17743097T
Other languages
English (en)
Polish (pl)
Inventor
Nitin Krishnaji Damle
Sanjay Nandlalji MANDHANE
Manoj Atmaramji UPADHYA
Sameer Vishwanath MEHETRE
Gajanan Uttamrao CHIDREWAR
Prabal Sengupta
Trinadha Rao Chitturi
Original Assignee
Sun Pharma Advanced Research Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Research Company Limited filed Critical Sun Pharma Advanced Research Company Limited
Publication of PL3463351T3 publication Critical patent/PL3463351T3/pl

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL17743097T 2016-06-02 2017-06-02 Leczenie choroby parkinsona PL3463351T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN201621019185 2016-06-02
IN201621019087 2016-06-02
EP17743097.2A EP3463351B1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease
PCT/IN2017/050224 WO2017208267A1 (en) 2016-06-02 2017-06-02 Treatment for parkinson's disease

Publications (1)

Publication Number Publication Date
PL3463351T3 true PL3463351T3 (pl) 2022-06-20

Family

ID=59388123

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17743097T PL3463351T3 (pl) 2016-06-02 2017-06-02 Leczenie choroby parkinsona

Country Status (26)

Country Link
US (4) US10849887B2 (enExample)
EP (2) EP4085912A1 (enExample)
JP (1) JP6974357B2 (enExample)
KR (1) KR102508288B1 (enExample)
CN (1) CN109475539B (enExample)
AU (1) AU2017273415B2 (enExample)
CL (1) CL2018003431A1 (enExample)
CY (1) CY1125285T1 (enExample)
DK (1) DK3463351T3 (enExample)
ES (1) ES2914782T3 (enExample)
HR (1) HRP20220683T1 (enExample)
HU (1) HUE059387T2 (enExample)
IL (1) IL263188B (enExample)
LT (1) LT3463351T (enExample)
MX (1) MX385276B (enExample)
MY (1) MY193754A (enExample)
NZ (1) NZ748592A (enExample)
PH (1) PH12018502457B1 (enExample)
PL (1) PL3463351T3 (enExample)
PT (1) PT3463351T (enExample)
RS (1) RS63243B1 (enExample)
SG (1) SG11201810294QA (enExample)
SI (1) SI3463351T1 (enExample)
SM (1) SMT202200228T1 (enExample)
UA (1) UA123018C2 (enExample)
WO (1) WO2017208267A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2844256B1 (en) 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
WO2017208267A1 (en) * 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease
CN110606840A (zh) 2018-06-15 2019-12-24 日产化学株式会社 5-炔基吡啶化合物的制造方法
EP3883935A4 (en) 2018-11-20 2022-08-10 Georgetown University COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE, MYODEGENERATIVE AND LYSOSOMA STORAGE DISEASES
CA3142899A1 (en) * 2019-06-11 2020-12-17 Sun Pharma Advanced Research Company Ltd. Treatment for synucleinopathies
WO2021030783A1 (en) * 2019-08-15 2021-02-18 Duke University Compositions and methods for the treatment cancer and cns disorders
WO2022024072A1 (en) 2020-07-31 2022-02-03 Sun Pharma Advanced Research Company Limited N'-(2-chloro-6-methylbenzoyl)-4-methyl-3-[2-(3-quinolyl) ethynyl]-benzohydrazide for treatment of alzheimer's disease
JP2025517624A (ja) 2022-05-02 2025-06-10 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド パーキンソン病の進行を低減するためのボドバチニブ
WO2025058473A1 (ko) 2023-09-14 2025-03-20 주식회사 엑소스템텍 퇴행성 뇌질환 치료 단백질을 포함하는 엑소좀을 이용한 뇌 특이적 퇴행성 뇌질환 치료 단백질 전달 기술

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012098416A1 (en) 2011-01-21 2012-07-26 Sun Pharma Advanced Research Company Ltd Diarylacetylene hydrazide containing tyrosine kinase inhibitors
EP2844256B1 (en) 2012-05-02 2023-02-22 Georgetown University Treating amyotrophic lateral sclerosis with tyrosine kinase inhibitors
CA2985161A1 (en) 2015-05-18 2016-11-24 Sun Pharma Advanced Research Company Limited Novel amidoheteroaryl aroyl hydrazide ethynes
WO2017208267A1 (en) * 2016-06-02 2017-12-07 Sun Pharma Advanced Research Company Limited Treatment for parkinson's disease

Also Published As

Publication number Publication date
UA123018C2 (uk) 2021-02-03
DK3463351T3 (da) 2022-06-07
HRP20220683T1 (hr) 2022-07-08
JP2019520344A (ja) 2019-07-18
EP4085912A1 (en) 2022-11-09
KR102508288B1 (ko) 2023-03-09
PH12018502457A1 (en) 2019-10-21
AU2017273415A1 (en) 2018-12-06
CN109475539A (zh) 2019-03-15
KR20190015257A (ko) 2019-02-13
MX385276B (es) 2025-03-18
RS63243B1 (sr) 2022-06-30
SMT202200228T1 (it) 2022-07-21
AU2017273415B2 (en) 2023-01-19
IL263188A (en) 2018-12-31
US20220273632A1 (en) 2022-09-01
BR112018074439A2 (pt) 2019-03-06
MY193754A (en) 2022-10-27
EP3463351B1 (en) 2022-04-27
PT3463351T (pt) 2022-06-02
CA3024976A1 (en) 2017-12-07
US10849887B2 (en) 2020-12-01
HUE059387T2 (hu) 2022-11-28
US20240066014A1 (en) 2024-02-29
ES2914782T3 (es) 2022-06-16
WO2017208267A1 (en) 2017-12-07
CL2018003431A1 (es) 2019-05-10
MX2018014944A (es) 2019-03-07
US20210015805A1 (en) 2021-01-21
NZ748592A (en) 2025-11-28
CY1125285T1 (el) 2025-03-28
LT3463351T (lt) 2022-06-10
PH12018502457B1 (en) 2022-01-12
IL263188B (en) 2021-08-31
US20190275017A1 (en) 2019-09-12
SG11201810294QA (en) 2018-12-28
EP3463351A1 (en) 2019-04-10
JP6974357B2 (ja) 2021-12-01
US11583522B2 (en) 2023-02-21
CN109475539B (zh) 2021-12-28
SI3463351T1 (sl) 2022-07-29
US11813252B2 (en) 2023-11-14

Similar Documents

Publication Publication Date Title
IL280530A (en) Decarboxylase aromatic amino acid-encoding phylonucleotides for the treatment of Parkinson's disease
IL324723A (en) Methods for treating Alzheimer's disease
SG11201912154XA (en) Aadc polynucleotides for the treatment of parkinson's disease
IL263188B (en) Treatment for Parkinson's disease
PL2968218T3 (pl) Skojarzenie do leczenia choroby parkinsona
IL247085A0 (en) Methods for treating Alzheimer's disease
EP3268086A4 (en) Lsd for the treatment of alzheimer's disease
ZA201605341B (en) Methods of treating alzheimer's disease
PL3285755T3 (pl) Chlorowodorek kreatyny do leczenia choroby Huntingtona
IL254252A0 (en) History of Tetrahydrofuran-Oahe Aminohydrothiazine Usefulness in the Treatment of Alzheimer's Disease
EP3244897A4 (en) Methods for treating alzheimer's disease
ZA201801945B (en) Compositions and methods for the treatment of parkinson's disease
DK3148588T3 (en) N,n-bis-2-mercaptoethyl isophthalamide for the treatment of parkinson's disease
ZA201807944B (en) Treatment for parkinson's disease
GB201518052D0 (en) Parkinson's disease treatment
HK40014282A (en) Methods for treating parkinson's disease
GB201504144D0 (en) Treatment of Parkinson's disease
GB201610205D0 (en) Therapies for parkinson's disease
GB201614863D0 (en) Alzheimer's disease
GB201511453D0 (en) Treatment of alzheimer's disease
GB201414038D0 (en) Alzheimer's disease